الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 67 |  |  |
| | | from | 67 | | |
Abstract
The spread of COVID-19 became an international public health crisis. Because of the gravity of this pandemic, developing a vaccine against COVID-19 has been a top priority for scientists throughout the world. Vaccines were the primary method practically every nation used to combat SARS-CoV-2 and put an end to the devastating outbreak. There are a number of vaccinations on the market, each with varying levels of success. Antibody response estimate is one method of measuring the host’s reaction to immunizations. Screening for anti SARS-CoV-2 S protein after immunization is a critical component in evaluating the success of several vaccinations.
The aim of the study was to detect anti SARS-CoV-2 S protein among recipients of Sinopharm vaccine, and to assess the factors associated with Sinopharm response.
Over the course of seven months, from January 2021 through August 2021, a cross-sectional study was conducted on 92 participants who received 2 doses of Sinopharm vaccine, 15-30 days after the second dose. They were screened for anti SARS-CoV-2 S protein.
The results of the present study revealed that:
1. The median age of the participants was 39 years ranging from 23 to 60 years.
2. Males constituted 58.7% while females comprised 41.3% of participants.
3. All participants were working in the medical field. The majority of them were physicians (46.7%) followed by medical technicians (20.7%), medical workers (12.0%), medical employees (8.7%), nurses (7.6%), and pharmacists (4.3 %).
4. Among the studied participants, 17.4% of them reported a history of SARS-CoV-2
infection before being vaccinated. They reported greater median antibody levels
than those who had not been infected before (76.00 Vs. 41.08 RU/ml).
5. The short-term adverse reactions following Sinopharm vaccination were detected in 35.9% of participants. Only 4.3% of participants noticed delayed symptoms or other symptoms resembling SARS-CoV-2 infection. All participants had no allergy to previous vaccination.
6. The majority of participants (95.7%) tested positive for anti SARS- COV-2 S protein. The anti SARS-COV-2 S protein levels ranged from 2 to 120 RU/ml with a median of 52.15 RU/ml.
7. Short term adverse reactions following Sinopharm vaccination were reported in 35.9% of participants. Pain or swelling at the injection site, headache, fatigue and fever were reported in 17.4%, 13%, 10.9% and 6.5% of participants, respectively. Participants who had fever after being vaccinated were positive for anti SARS- COV-2 S protein with a median of 55.84 RU/ml.
8. Anti SARS-COV-2 S protein was positive in all participants receiving treatment for diabetes, hypertension, thyroid diseases, asthma or any lung condition, or allergy. Hypertensive participants had higher anti SARS-COV-2 S protein with a median of 101.18 RU/ml.
9. The majority of smoker participants (90%) were positive for anti SARS-COV-2 S protein. The median titer of anti SARS-COV-2 S protein was 46.92 RU/ml in smokers Vs. 57.08 RU/ml in non-smokers.
6.2. Conclusion
from this study, it can be concluded that:
1. The majority of participants (95.7%) have developed anti SARS- COV-2 S protein (15 to 30) days after the second dose of vaccination.
2. Those who had previously been infected with SARS-CoV-2 and received the vaccine had significantly greater median antibody levels (76.00RU/ml) than those who had not (41.08RU/ml).
3. There was no significant association between anti SARS-CoV-2 S protein with sociodemographic characteristics (age, sex and occupation).
4. Short term adverse reaction such as: pain or swelling at the injection site, headache, fatigue and fever were the most denoted reactions among participants after vaccination.
5. Neither the participants’ medical status, any chronic illness, nor their smoking habits affected in any means in their results.
6.3. Recommendations
from the results of the present study, the following recommendations are suggested:
1. Encouraging the use of Sinopharm vaccine as a means of SARS-COV-2 protection.
2. More studies are needed to determine the effect of extreme of age (children, and
elderly) on antibody production following vaccination.
3. Further studies testing the neutralizing effect of anti SARS-COV-2 S protein should be considered.